With its hefty helpings of red meat and dishes with names like bulgogi, Korean food is not always associated with eating light. But kimchi, a sour Korean staple made from fermented radish and cabbage, seems to help people stay in shape as they get older. That's according to a paper published by the British Medical Journal's BMJ Open, in which researchers claim "eating up to three daily servings of the Korean classic, kimchi, may lower men’s overall risk of obesity." The team, from Chung Ang Univ
AstraZeneca moved on Thursday to boost its drugs pipeline in the booming anti-obesity market, saying it would pay China's Eccogene up to about $2 billion for an exclusive licence to develop an experimental oral drug in the field. The Anglo-Swedish drugmaker said it had struck the deal for ECC5004, a once-daily oral drug that is part of a class of highly promising weight-loss medicines known as GLP-1 receptor agonists currently dominated by Novo Nordisk and Eli Lilly, which have injectable products. Astra, alongside reporting quarterly results, said Eccogene would receive $185 million up front, plus up to $1.825 billion depending on certain clinical, regulatory, and commercial achievements.
Danish drugmaker Novo Nordisk reported Thursday a sharp rise in third quarter sales and profits driven by the success of its anti-diabetes and anti-obesity treatments Ozempic and Wegovy.In its quarterly report, Novo Nordisk maintained its annual outlook of an increase in annual operating profit of between 40 and 46 percent on a rise in sales of between 32 and 38 percent.
cbw/jll/rl